Gene Therapy vs. Stem Cell Therapy: What's the Difference?

What This Article Covers

“Gene therapy” and “stem cell therapy” get used almost interchangeably in headlines, ads, and casual conversation, but they describe two genuinely different tools that medicine uses to fix different kinds of problems — one edits or replaces instructions inside cells, the other replaces or repairs the cells themselves. This article breaks down what each one actually is in plain terms, walks through real FDA-approved examples of each so you can see the difference in action, explains why some cutting-edge treatments like CAR-T cell therapy are honestly both at once, and gives you a simple framework for cutting through marketing language when researching a treatment for yourself or a loved one.

What Is Gene Therapy?

Gene therapy works on the level of DNA — the instruction manual inside your cells. According to the National Institutes of Health, gene therapy aims to treat or prevent disease by correcting the underlying genetic problem, either by delivering a working copy of a gene that isn't functioning properly, or by directly editing existing DNA with tools like CRISPR-Cas9 to add, remove, or fix specific genetic sequences (MedlinePlus Genetics/NIH). Because DNA can't just be dropped into a cell on its own, gene therapies rely on a delivery vehicle called a vector — most often a modified, harmless virus (commonly an adeno-associated virus, or AAV) that “infects” target cells and drops off the corrected genetic material. The gene therapy can be given directly to the patient (in vivo), or cells can be removed from the body, edited in a lab, and infused back (ex vivo) — which is exactly how Casgevy, the first CRISPR-based medicine approved in the U.S., works for sickle cell disease (STAT News, 2023).

What Is Stem Cell Therapy?

Stem cell therapy works on the level of whole cells, not DNA instructions. Stem cells are the body's raw material — cells that can renew themselves through division and, under the right signals, mature (“differentiate”) into more specialized cell types, like blood cells, cartilage, or nerve cells (NIH Stem Cell Basics). There are several categories: embryonic stem cells and induced pluripotent stem cells (iPSCs, adult cells reprogrammed back to an earlier, flexible state) can theoretically become almost any cell type in the body, while adult stem cells — like the blood-forming (hematopoietic) stem cells in bone marrow — are already committed to producing specific tissue types. In therapy, the goal is typically to replace damaged or missing cells, rebuild a tissue system, or calm an overactive immune response — not to fix a gene sequence.

How Each One Actually Works, Side by Side

Think of it this way: gene therapy rewrites or supplements a cell's software; stem cell therapy provides new hardware. A gene therapy for an inherited retinal disease (Luxturna) delivers a corrected copy of a gene directly into existing eye cells so those same cells can start making a protein they were missing. A stem cell therapy, by contrast — like a bone marrow or umbilical cord blood transplant — replaces a patient's diseased or destroyed blood-forming system with healthy donor stem cells that then grow into a whole new supply of blood and immune cells. Neither approach is “better” in the abstract; they solve fundamentally different problems, and increasingly, researchers combine them.

Where the Lines Blur: CAR-T and Gene-Edited Cell Therapies

This is where newcomers usually get confused, and the confusion is reasonable — because some of today's most talked-about treatments are legitimately both. CAR T-cell therapy is the clearest example. It starts with a cell therapy step (a patient's own T cells are collected) and then adds a gene therapy step (those T cells are genetically engineered in a lab to grow chimeric antigen receptors, or CARs, on their surface, so they can recognize and attack cancer). The engineered cells are multiplied into the hundreds of millions and infused back into the patient (National Cancer Institute). The FDA and researchers classify CAR-T products, including Kymriah, Yescarta, Breyanzi, Abecma, Carvykti, and Tecartus, under the umbrella of “cellular and gene therapy products” for exactly this reason. Casgevy is another hybrid: it uses CRISPR gene-editing technology, but the “product” is the patient's own CRISPR-edited hematopoietic stem cells, harvested, edited, and returned via a transplant procedure.

Real, FDA-Approved Examples Today

It's worth being precise here, because this space attracts a lot of hype. As of 2026, the FDA's list of approved cellular and gene therapy products includes:

• Gene therapies: Luxturna (inherited retinal disease), Zolgensma (spinal muscular atrophy), Hemgenix and Roctavian (hemophilia B and A), Casgevy and Lyfgenia (sickle cell disease), Elevidys (Duchenne muscular dystrophy), among others (FDA Approved Cellular and Gene Therapy Products page).
• CAR-T (gene-modified cell) therapies: Kymriah, Yescarta, Breyanzi, Abecma, Carvykti, Tecartus, and others, approved for specific blood cancers.
• Non-gene-modified cell therapies: FDA-licensed cord blood (hematopoietic progenitor cell) products used in stem cell transplants for blood cancers and blood disorders, and, notably, Ryoncil (remestemcel-L), approved in December 2024 as the first mesenchymal stromal cell therapy licensed in the U.S., for steroid-refractory acute graft-versus-host disease in children.

It's also worth knowing that routine bone marrow and cord blood transplantation — used for decades to treat leukemia, lymphoma, and other blood disorders — is the most well-established, evidence-backed form of stem cell therapy in practice today, even though it isn't a single “approved drug” in the way a gene therapy is; it's a licensed cellular product used within a standardized medical procedure.

How to Think About This as a Patient or Newcomer

When researching a treatment — for yourself, a family member, or just out of curiosity — two questions cut through most of the confusion. First: is this altering my genetic instructions, or is it replacing/adding cells? That tells you whether you're looking at a gene therapy, a cell therapy, or (increasingly often) both. Second, and more importantly: is this specific product actually FDA-approved for my specific condition, or is it “investigational,” “experimental,” or being offered off-label at a clinic? The FDA has repeatedly warned that many clinics market “stem cell therapies” for conditions like arthritis, autism, or anti-aging that have no approved product and no solid clinical trial evidence behind them, and that these unapproved injections have caused serious harm, including infections and vision loss, in real patients (FDA Patient and Consumer Warning). A legitimate FDA approval will always be tied to a specific product name and a specific indication — not a vague promise that “stem cells” or “gene therapy” as broad categories will help.

Bottom Line

Gene therapy and stem cell therapy are two distinct scientific strategies — one edits or supplies genetic instructions, the other replaces or restores cells — and both have produced real, FDA-approved treatments for serious diseases, from inherited blindness and sickle cell disease to specific blood cancers. Some of the most exciting therapies available today, like CAR-T and Casgevy, blend both approaches into a single “cell and gene therapy” product. The single most useful habit for a newcomer is to always ask whether a specific product has FDA approval for the specific condition being discussed, since the term “stem cell therapy” in particular is widely used by clinics offering treatments with no such approval behind them.